Identity:

Title: MD, PhD, FESC, FHFA Family Name(s): Chioncel First Name(s): Ovidiu

Age: 56

Application for the following position in the HFA Board or Nominating Committee:

President-Elect



Place of work

If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.

	, , ,
Institute/organisation:	Emergency Institute for Cardiovascular Diseases "C.C.Iliescu", Bucharest
Department:	ICCU and Cardiology 1 st Department
Address:	Fundeni str no 258, sect 2, Bucharest
Post code / Zip:	022328
Country:	Romania

General Curriculum Vitae (500 words max)

Please also include your H index and top 5 to 10 publications in the last 5 years

I am Professor of Cardiology at the University of Medicine and Pharmacy, Carol Davila, Bucharest, and I currently lead ICCU and Cardiology 1st Department at the Institute of Emergency for Cardiovascular Diseases- C.C.Iliescu, Bucharest, Romania.

I obtained my PhD from UMF Carol Davila in 2012, with research focusing on the role of proinflammatory cytokines in reverse remodelling. In 2018, I sustained my habilitation on the Epidemiology of Acute Heart Failure.

I completed my medical education at University of Medicine Carol Davila in 1992, became a specialist (1998) and consultant in cardiology (2003). I am certified in Echocardiography and Intensive Care. My post graduate education encompasses extensive trainings, including Echocardiography at Instituto Clinico Humanitas, Milan, Italy (1998), heart transplantation and myocardial biopsies at Universitat Klinikum Munster, Germany (2000), advanced echocardiography and cardiac CT at Cardiocentro Ticino Switzerland (2006), heart transplant and ventricular assist devices, Sheba Medical Center, Israel (2014), and ventricular assist devices at Universitat Klinikum, Leiden, Netherlands (2015).

Since 2014, I am leading the largest Intensive Cardiac Care Unit (ICCU) in Romania, specialized in critical care patients, including those with mechanical circulatory support and post ventricular assist device implant.

In 2019, I was selected by the Romanian Health Ministry to lead the reorganization of ICCUs across hospitals in Romania. Within the framework of a World Bank funded project (13M EUR), I developed new national quality standards for ICCU accreditation. This initiative enabled the use of project funds to modernize equipment and certify 15 ICCUs. In recognition of this work, I received

the Medical Knight medal from the Romanian Presidency in December 2019. In 2021, I was appointed Vice-President of the Romanian Health Ministry's Expert Commission.

Since 2023, I am President of Romanian Society of Cardiology (RSC). Previous elected positions in RSC include President of Working Group of HF, Treasurer, Secretary and President-Elect. I represented RSC in EU Parliament, Bruxelles (2017 & 2019).

I coordinated five national research grants obtained by competion.

I designed the first Acute Heart Failure national registry from Eastern Europe, the RO-AHFS study (published in AHJ 2011), I am the Director of Romanian National Registry of Acute Aortic Dissections (RENADA-RO) and Romanian Registry of Iron Defficiency in Heart Failure (FERIC-RO). Since 2010, I have been contributing to HFA-ESC related activities, working in various committees. I was the National Coordinator for ESC-HF-pilot study, ESC-HF-LT-registry and ESC-HF-III. I was member of ESC-EORP Oversight Committee and Executive Committee and since 2023, I am chair of GRASP-HF.

I was member in the Executive Committee of two large RCTs (SEISMIC and STRONG-HF), member of the Steering Committee of five RCTs, and National Coordinator for 23 RCTs.

I am Associate-Editor for BMC-Cardiovascular Disorders, Journal of Acute Diseases, Cardiac Failure Review, ESC-Heart Failure, Exploration of Medicine, Heart Failure Reviews and Bulgarian Journal of Cardiology.

I have authored four monographs about heart failure, and I am the first author of six chapters in international textbooks. I have contributed to over 300 original papers, with an H-Index of 46 (WoS Clarivate) and 50 (Scopus).

<u>Selected publications:</u>

<u>Chioncel O</u>, Adamo M, Nikolaou M, et all. Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute Cardio Vascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. **Eur J Heart Fail**. 2023 Jul;25(7):1025-1048.

Adamo M, <u>Chioncel O</u>, Pagnesi M et all. Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. **Eur J Heart Fail**. 2023 Dec 22. doi: 10.1002/ejhf.3106.

<u>Chioncel O</u>, Davison B, Adamo M et all. Non-cardiac comorbidities and intensive up-titration of oral treatment in patients recently hospitalized for heart failure: Insights from the STRONG-HF trial. **Eur J Heart Fail**. 2023 Nov;25(11):1994-2006.

<u>Chioncel O</u>, Benson L, Crespo-Leiro MG, Anker SD, Coats AJS, Filippatos G, McDonagh T, Margineanu C, Mebazaa A, Metra M, Piepoli MF, Adamo M, Rosano GMC, Ruschitzka F, Savarese G, Seferovic P, Volterrani M, Ferrari R, Maggioni AP, Lund LH. Comprehensive characterization of non-cardiac comorbidities in acute heart failure: an analysis of ESC-HFA EURObservational Research Programme Heart Failure Long-Term Registry. **Eur J Prev Cardiol**. 2023 Sep 20;30(13):1346-1358

Vazir A, Kapelios CJ, Agaoglu E, Metra M, Lopatin Y, Seferovic P, Mullens W, Filippatos G, Rosano G, Coats AJS, <u>Chioncel O</u>. Decongestion strategies in patients presenting with acutely decompensated heart failure: A worldwide survey among physicians. **Eur J Heart Fail**. 2023 Sep;25(9):1555-1570.

Mebazaa A, Davison B, <u>Chioncel O</u>, et all.Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. **Lancet**. 2022 Dec 3;400(10367):1938-1952.

Palazzuoli A, Metra M, Collins SP, Adamo M, Ambrosy AP, Antohi LE, Ben Gal T, Farmakis D, Gustafsson F, Hill L, Lopatin Y, Tramonte F, Lyon A, Masip J, Miro O, Moura B, Mullens W, Radu RI, Abdelhamid M, Anker S, Chioncel O. Heart failure during the COVID-19 pandemic: clinical, diagnostic, management, and organizational dilemmas. **ESC Heart Fail**. 2022 Dec;9(6):3713-3736.

Metra M, <u>Chioncel O</u>, Cotter G, Davison B, Filippatos G, Mebazaa A, Novosadova M, Ponikowski P, Simmons P, Soffer J, Simonson S. Safety and efficacy of istaroxime in patients with acute heart failure-related precardiogenic shock - a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC). **Eur J Heart Fail**. 2022 Oct;24(10):1967-1977.

Radu RI, Ben Gal T, Abdelhamid M, Antohi EL, Adamo M, Ambrosy AP, Geavlete O, Lopatin Y, Lyon A, Miro O, Metra M, Parissis J, Collins SP, Anker SD, <u>Chioncel O</u>. Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature. **ESC Heart Fail**. 2021 Dec;8(6):4717-4736.

<u>Chioncel O</u>, Parissis J, Mebazaa A, Thiele H,et all. Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology. **Eur J Heart Fail**. 2020 Aug;22(8):1315-1341.

<u>Chioncel O</u>, Mebazaa A, Maggioni AP, et all.. Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. **Eur J Heart Fail**. 2019 Nov;21(11):1338-1352.

Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society 150 words maximum

Since 2018, I have been serving the HFA-Board, as Coordinator of AHF Committee (2018-2024), Coordinator of Valvular Heart Disease Study Group (2020-2022), Coordinator of National HF Societies (2020-2022) and Treasurer (2022-2024). I am Task-Force member of the ICARe-HF and I have actively contributed to the development of the accreditation process and fund raising. I have developed and lead the long-term project "Reciprocal Basic Science – Clinical Science interaction (HFA-BOOSTer), in collaboration with HFA-Basic Science Committee, aiming to promote reciprocal education and training of next-generation of HF specialists.

I was member of the ESC/EORP Oversight Committee (2018- 2020) and Executive Committee (2020- 2022), member of ESC Valve Council (2020-2022). Since 2023, I am the chair of GRASP-HF. I was member of the Task-Force for "2021-ESC-Guidelines for HF" and "2023-Focused Update of the ESC-Guidelines" and ESC-reviewer for "2019 ESC Guidelines on diabetes, pre-diabetes".

Since 2023, I am the President of Romanian Society of Cardiology.

Why are you motivated to join the HFA Board or Nominating Committee? 150 words maximum

My experience in clinical practice, research, education, management and leadership positions in RSC and ESC/HFA, has equipped me with a comprehensive understanding of the HFA community's needs and the responsibility of various roles. Aspiring to the HFA President-Elect position, I plan to leverage these insights to foster a culture that promotes innovation, inclusivity, and collaboration, ensuring that HFA stands as a pillar of excellence, where every member is valued and empowered. I aim to open new possibilities for innovative training and research and create opportunities for the next generation of HF specialists, ensuring their active participation in HFA initiatives. I intend to strengthen HFA by expanding international partnerships with other societies. I am committed to ensuring that HFA aligns to and actively promotes the ESC values, working collectively towards the advancement of HF care and research globally. My commitment extends to every HFA member, ensuring our efforts strengthen the HFA.

How will you combine your HFA position with your daily clinical/research workload? 80 words maximum

Leveraging my decade-long involvement with the HFA and the RSC, I am well-prepared to integrate the presidency role with my clinical and research activities. My past experiences have equipped me with the skills to delegate effectively, ensuring that all tasks are managed efficiently without compromising quality. I have arranged with my university to have protected time for HFA responsibilities (three full-time-equivalents), if elected. I anticipate no significant challenges in maintaining high standards in both my HFA duties and clinical/research work.